Skip to main content
APLS
NASDAQ Life Sciences

阿佩利斯飙升140%：被拜尔健收购560亿美元扩大罕见疾病产品线

feedReported by Reuters
Sentiment info
Positive
Importance info
9
Price
$41.06
Mkt Cap
$2.185B
52W Low
$16.1
52W High
$30.48
Market data snapshot near publication time

summarizeSummary

拜尔健已经同意以大约560亿美元的现金收购阿佩利斯制药公司，每股提供41美元，加上最高4美元的潜在附条件权益，这与阿佩利斯的眼部疾病药物Syfovre的全球销售里程碑挂钩。这代表了阿佩利斯上一收盘价的140%溢价，导致其股价在盘前交易中翻倍以上。对于阿佩利斯来说，这是一次具有重大股东回报的明确退出。对于拜尔健来说，这次收购大大扩大了其罕见疾病产品线，在最近的新许可协议、2期研究阳性结果和Spinraza获得FDA批准的基础上，这表明了对管道增长的战略推动。投资者现在将关注交易的完成和阿佩利斯资产的成功整合，特别是Syfovre的商业表现。

在该公告发布时，APLS的交易价格为$41.06，交易所为NASDAQ，所属行业为Life Sciences，市值约为$21.8亿。 52周交易区间为$16.10至$30.48。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed APLS - Latest Insights

APLS
Apr 14, 2026, 7:40 AM EDT
Filing Type: SC 14D9
Importance Score:
10
Apellis Board Unanimously Recommends Biogen's $41.00 Cash + CVR Tender Offer, Citing Significant Premium
Sentiment: Positive
View Wiseek Article
APLS
Apr 14, 2026, 7:02 AM EDT
Filing Type: SC TO-T
Importance Score:
10
Biogen Launches Tender Offer to Acquire Apellis for $41.00 Cash Plus CVR, Totaling Up to $45.00 Per Share
Sentiment: Positive
View Wiseek Article
APLS
Apr 06, 2026, 6:08 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Acquirer Biogen Secures 14.2% Insider Support for Apellis Tender Offer
Sentiment: Positive
View Wiseek Article
APLS
Apr 06, 2026, 4:02 PM EDT
Filing Type: SC14D9C
Importance Score:
7
Apellis Details Employee Equity, Compensation, and Severance Plans for Biogen Merger
Sentiment: Neutral
View Wiseek Article
APLS
Mar 31, 2026, 5:30 PM EDT
Filing Type: SC14D9C
Importance Score:
10
Apellis Board Unanimously Recommends Biogen's $5.6B Acquisition Offer at $41/Share Plus CVR
Sentiment: Positive
View Wiseek Article
APLS
Mar 31, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
10
Apellis to be Acquired by Biogen for $5.6 Billion in Cash and CVRs
Sentiment: Positive
View Wiseek Article
APLS
Mar 31, 2026, 5:08 PM EDT
Filing Type: SC TO-C
Importance Score:
10
Biogen Launches Tender Offer to Acquire Apellis for $41/Share Cash Plus CVRs, Valuing Company at $5.6 Billion
Sentiment: Positive
View Wiseek Article
APLS
Mar 31, 2026, 5:01 PM EDT
Filing Type: SC TO-C
Importance Score:
10
Biogen Launches $5.6B Tender Offer to Acquire Apellis for $41/Share Plus CVRs
Sentiment: Positive
View Wiseek Article
APLS
Mar 31, 2026, 7:19 AM EDT
Source: Reuters
Importance Score:
9
Apellis Soars 140% on $5.6 Billion Biogen Acquisition to Expand Rare Disease Portfolio
Sentiment: Positive
View Wiseek Article
APLS
Feb 24, 2026, 6:56 AM EST
Filing Type: 10-K
Importance Score:
8
Apellis Pharmaceuticals Achieves Profitability in 2025 with Strong Revenue Growth and Strategic Deals
Sentiment: Positive
View Wiseek Article